The PFS hazard ratio ( HR ) ( selumetinib : placebo ) was 0.75 [ 90 % confidence interval ( CI ) 0.50-1 .14 ; P = 0.130 ] , with a median PFS of 4.23 months ( 90 % CI 3.63-6 .90 ) for docetaxel plus selumetinib and 3.93 months ( 90 % CI 2.07-4 .16 ) for docetaxel alone .